

# Author's Accepted Manuscript

Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptor

Haruna Sasaki-Iwaoka, Makoto Ohori, Akira Imasato, Katsunari Taguchi, Kyoko Minoura, Tetsu Saito, Kiyoshi Kushima, Emiko Imamura, Satoshi Kubo, Shigetada Furukawa, Tatsuaki Morokata



PII: S0014-2999(18)30196-1  
DOI: <https://doi.org/10.1016/j.ejphar.2018.03.036>  
Reference: EJP71740

To appear in: *European Journal of Pharmacology*

Received date: 6 December 2017  
Revised date: 22 March 2018  
Accepted date: 23 March 2018

Cite this article as: Haruna Sasaki-Iwaoka, Makoto Ohori, Akira Imasato, Katsunari Taguchi, Kyoko Minoura, Tetsu Saito, Kiyoshi Kushima, Emiko Imamura, Satoshi Kubo, Shigetada Furukawa and Tatsuaki Morokata, Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptor, *European Journal of Pharmacology*, <https://doi.org/10.1016/j.ejphar.2018.03.036>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptor**

**Haruna Sasaki-Iwaoka<sup>\*</sup>, Makoto Ohori, Akira Imasato, Katsunari Taguchi, Kyoko Minoura, Tetsu Saito, Kiyoshi Kushima, Emiko Imamura, Satoshi Kubo, Shigetada Furukawa, Tatsuaki Morokata**

Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan

**\*Corresponding author. Haruna Sasaki-Iwaoka** Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan Tel.: +81-29-863-6524. haruna.iwaoka@astellas.com

**Abstract**

Interleukin (IL)-12 and IL-23 share a common subunit (p40) and function in T-helper (Th) 1 and Th17 immunity, respectively. Anti-IL-12/23p40 and specific anti-IL-23 antibodies are currently in clinical use for psoriasis and undergoing trials for autoimmune diseases. Since expression levels of the IL-23 receptor are likely to be much lower than those of IL-23, an anti-IL-23 receptor antibody might offer greater promise in inhibiting the IL-23-IL-17 pathways involved in inflammatory disorders. To our knowledge, no anti-IL-23 receptor antibody has been trialed in clinical studies to date. This study describes the generation and characterization of AS2762900-00, a fully human monoclonal antibody against the IL-23 receptor. AS2762900-00 bound both

Download English Version:

<https://daneshyari.com/en/article/8529115>

Download Persian Version:

<https://daneshyari.com/article/8529115>

[Daneshyari.com](https://daneshyari.com)